6785 Stock Overview
A drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Alar Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$152.00 |
| 52 Week High | NT$465.00 |
| 52 Week Low | NT$152.00 |
| Beta | 0.11 |
| 11 Month Change | -11.37% |
| 3 Month Change | -19.15% |
| 1 Year Change | -23.04% |
| 33 Year Change | 204.00% |
| 5 Year Change | n/a |
| Change since IPO | 237.78% |
Recent News & Updates
Shareholder Returns
| 6785 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -7.0% | -0.5% | -0.6% |
| 1Y | -23.0% | 10.6% | 33.9% |
Return vs Industry: 6785 underperformed the TW Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: 6785 underperformed the TW Market which returned 37.7% over the past year.
Price Volatility
| 6785 volatility | |
|---|---|
| 6785 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6785's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6785's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 22 | Yung-Shun Wen | www.alarpharm.com |
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals Inc. Fundamentals Summary
| 6785 fundamental statistics | |
|---|---|
| Market cap | NT$10.15b |
| Earnings (TTM) | NT$400.72m |
| Revenue (TTM) | NT$474.29m |
25.3x
P/E Ratio21.4x
P/S RatioIs 6785 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6785 income statement (TTM) | |
|---|---|
| Revenue | NT$474.29m |
| Cost of Revenue | NT$2.03m |
| Gross Profit | NT$472.26m |
| Other Expenses | NT$71.54m |
| Earnings | NT$400.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.00 |
| Gross Margin | 99.57% |
| Net Profit Margin | 84.49% |
| Debt/Equity Ratio | 0% |
How did 6785 perform over the long term?
See historical performance and comparison